Moreover, currently available ICB antibodies aiming to enhance tumor cell recognition by lymphocytes and T cell cytotoxicity, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4, have shown great promise in clinical use53. Here, CD274 is linked to neoplasm.